Axovant Sciences Ltd. (AXON) Given a $35.00 Price Target at HC Wainwright
A number of other equities research analysts also recently weighed in on the stock. Cowen and Company assumed coverage on shares of Axovant Sciences in a research note on Tuesday. They set an outperform rating on the stock. Piper Jaffray Companies reiterated a positive rating and set a $32.00 price target on shares of Axovant Sciences in a research note on Monday. Oppenheimer Holdings, Inc. set a $20.00 price target on shares of Axovant Sciences and gave the stock a buy rating in a research note on Thursday, February 9th. Zacks Investment Research downgraded shares of Axovant Sciences from a hold rating to a sell rating in a research note on Tuesday, February 7th. Finally, Robert W. Baird reiterated a positive rating and set a $29.00 price target on shares of Axovant Sciences in a research note on Tuesday, December 20th. Two analysts have rated the stock with a sell rating and nine have given a buy rating to the stock. The stock has an average rating of Buy and a consensus target price of $25.32.
Axovant Sciences (NYSE:AXON) traded up 2.63% during trading on Tuesday, reaching $12.09. 908,232 shares of the company’s stock traded hands. The company’s market capitalization is $1.20 billion. The firm’s 50 day moving average is $12.52 and its 200-day moving average is $13.84. Axovant Sciences has a 12 month low of $9.92 and a 12 month high of $17.66.
Axovant Sciences (NYSE:AXON) last posted its quarterly earnings results on Tuesday, February 14th. The company reported ($0.48) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.45) by $0.03. Analysts expect that Axovant Sciences will post ($1.65) EPS for the current fiscal year.
This article was posted by Daily Political and is the property of of Daily Political. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this article can be viewed at http://www.dailypolitical.com/2017/02/16/axovant-sciences-ltd-axon-given-a-35-00-price-target-at-hc-wainwright.html.
Several large investors have recently modified their holdings of the stock. Bourgeon Capital Management LLC increased its stake in shares of Axovant Sciences by 12.1% in the second quarter. Bourgeon Capital Management LLC now owns 23,200 shares of the company’s stock valued at $298,000 after buying an additional 2,500 shares in the last quarter. Ameriprise Financial Inc. purchased a new stake in shares of Axovant Sciences during the second quarter valued at approximately $786,000. Nationwide Fund Advisors increased its stake in shares of Axovant Sciences by 14.8% in the second quarter. Nationwide Fund Advisors now owns 49,529 shares of the company’s stock valued at $636,000 after buying an additional 6,382 shares in the last quarter. Ghost Tree Capital LLC purchased a new stake in shares of Axovant Sciences during the second quarter valued at approximately $7,383,000. Finally, Sabby Management LLC increased its stake in shares of Axovant Sciences by 458.2% in the second quarter. Sabby Management LLC now owns 190,000 shares of the company’s stock valued at $2,440,000 after buying an additional 155,960 shares in the last quarter.
About Axovant Sciences
Axovant Sciences Ltd. is a Bermuda-based clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.